M&A Deal Summary

DSM-Firmenich Acquires Vitatene S.A.

On May 10, 2011, DSM-Firmenich acquired life science company Vitatene S.A.

Acquisition Highlights
  • This is DSM-Firmenich’s 4th transaction in the Life Science sector.
  • This is DSM-Firmenich’s 1st transaction in Spain.

M&A Deal Summary

Date 2011-05-10
Target Vitatene S.A.
Sector Life Science
Buyer(s) DSM-Firmenich
Deal Type Add-on Acquisition

Target

Vitatene S.A.

Leon, Spain
Vitatene S.A. is a producer of natural carotenoids. Vitatene is engaged in the production and sale of a range of high-value natural carotenoid products derived from fermentation of the fungus Blakeslea trispora.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

DSM-Firmenich

Kaiseraugst, Switzerland

Category Company
Founded 1902
Sector Chemicals
Employees26,301
Revenue 12.8B EUR (2024)
DESCRIPTION

DSM-Firmenich specializes in the development, manufacture, and marketing of performance materials, nutritional and pharmaceutical ingredients, and industrial chemicals. The products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing, and electrics & electronics. DSM-Firmenich was founded in 1902 and is based in Kaiseraugst, Switzerland.


DEAL STATS #
Overall 11 of 28
Sector: Life Science M&A 4 of 9
Type: Add-on Acquisition M&A Deals 10 of 19
Country: Spain M&A 1 of 1
Year: 2011 M&A 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-05-04 Fatrom Feed Additives

Ştefăneştii de Jos,, Romania

Fatrom - feed additives Ltd. manufactures premix for livestock feed market.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-03-26 Verenium - Food Enzymes Business and Key Technology

United States

Verenium - Food Enzymes Business and Key Technology comprises oilseed processing services and food enzymes and access to biodiversity libraries that Verenium uses proprietary technology.

Buy $37M